{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:42:52Z","timestamp":1780393372332,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02972-8","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T18:11:42Z","timestamp":1750443102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Unusual phenomenon in advanced hepatocellular carcinoma: declining alpha-fetoprotein levels despite disease progression"],"prefix":"10.1007","volume":"16","author":[{"given":"Haoran","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"issue":"3","key":"2972_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"2972_CR2","doi-asserted-by":"publisher","first-page":"1090895","DOI":"10.3389\/fphar.2023.1090895","volume":"14","author":"L Dong","year":"2023","unstructured":"Dong L, Zhou S, Bai X, He X. Construction of a prognostic model for HCC based on ferroptosis-related LncRNAs expression and its potential to predict the response and IrAEs of immunotherapy. Front Pharmacol. 2023;14:1090895. https:\/\/doi.org\/10.3389\/fphar.2023.1090895.","journal-title":"Front Pharmacol"},{"issue":"10125","key":"2972_CR3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nik\u0161i\u0107 M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37\u2008513\u2008025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(17)33326-3.","journal-title":"Lancet"},{"issue":"26","key":"2972_CR4","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960\u201370. https:\/\/doi.org\/10.1200\/JCO.20.00808.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2972_CR5","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol. 2021;22(7):977\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(21)00252-7.","journal-title":"Lancet Oncol"},{"issue":"10408","key":"2972_CR6","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402(10408):1133\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(23)00961-3.","journal-title":"Lancet"},{"issue":"3\u20134","key":"2972_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1159\/000343872","volume":"3","author":"JL Raoul","year":"2014","unstructured":"Raoul JL, Park JW, Kang YK, Finn RS, Kim JS, Yeo W, et al. Using modified RECIST and alpha-fetoprotein levels to assess treatment benefit in hepatocellular carcinoma. Liver Cancer. 2014;3(3\u20134):439\u201350. https:\/\/doi.org\/10.1159\/000343872.","journal-title":"Liver Cancer"},{"issue":"58","key":"2972_CR8","doi-asserted-by":"publisher","first-page":"97758","DOI":"10.18632\/oncotarget.22050","volume":"8","author":"T Wang","year":"2017","unstructured":"Wang T, Zhang KH, Hu PP, Wan QS, Han FL, Zhou JM, et al. Combination of dual serum fluorescence, AFP and hepatic function tests is valuable to identify HCC in AFP-elevated liver diseases. Oncotarget. 2017;8(58):97758\u201368. https:\/\/doi.org\/10.18632\/oncotarget.22050.","journal-title":"Oncotarget"},{"issue":"10","key":"2972_CR9","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00432-020-03331-6","volume":"146","author":"Y Zheng","year":"2020","unstructured":"Zheng Y, Zhu M, Li M. Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2020;146(10):2439\u201346. https:\/\/doi.org\/10.1007\/s00432-020-03331-6.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"16","key":"2972_CR10","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1158\/1078-0432.CCR-21-3275","volume":"28","author":"AX Zhu","year":"2022","unstructured":"Zhu AX, Dayyani F, Yen CJ, Ren Z, Bai Y, Meng Z, et al. Alpha-fetoprotein as a potential surrogate biomarker for atezolizumab\u2009+\u2009bevacizumab treatment of hepatocellular carcinoma. Clin Cancer Res. 2022;28(16):3537\u201345. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3275.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2972_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1055\/s-0039-1677768","volume":"39","author":"F Trevisani","year":"2019","unstructured":"Trevisani F, Garuti F, Neri A. Alpha-fetoprotein for diagnosis, prognosis, and transplant selection. Semin Liver Dis. 2019;39(2):163\u201377. https:\/\/doi.org\/10.1055\/s-0039-1677768.","journal-title":"Semin Liver Dis"},{"key":"2972_CR12","doi-asserted-by":"publisher","first-page":"807189","DOI":"10.3389\/fonc.2022.807189","volume":"12","author":"B Liu","year":"2022","unstructured":"Liu B, Shang X, Shi JY, Cui GZ, Li X, Wang NY. Early alpha-fetoprotein response is associated with survival in patients with HBV-related hepatocellular carcinoma receiving lenvatinib. Front Oncol. 2022;12:807189. https:\/\/doi.org\/10.3389\/fonc.2022.807189.","journal-title":"Front Oncol"},{"issue":"1","key":"2972_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41416-018-0103-0","volume":"119","author":"I Chau","year":"2018","unstructured":"Chau I, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, et al. Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. Br J Cancer. 2018;119(1):19\u201326. https:\/\/doi.org\/10.1038\/s41416-018-0103-0.","journal-title":"Br J Cancer"},{"key":"2972_CR14","doi-asserted-by":"publisher","first-page":"982983","DOI":"10.3389\/fonc.2022.982983","volume":"12","author":"AM Berz","year":"2022","unstructured":"Berz AM, Dromain C, Vietti-Violi N, Boughdad S, Duran R. Tumor response assessment on imaging following immunotherapy. Front Oncol. 2022;12:982983. https:\/\/doi.org\/10.3389\/fonc.2022.982983.","journal-title":"Front Oncol"},{"issue":"5","key":"2972_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.5306\/wjco.v12.i5.323","volume":"12","author":"D Ippolito","year":"2021","unstructured":"Ippolito D, Maino C, Ragusi M, Porta M, Gandola D, Franzesi CT, et al. Immune response evaluation criteria in solid tumors for assessment of atypical responses after immunotherapy. World J Clin Oncol. 2021;12(5):323\u201334. https:\/\/doi.org\/10.5306\/wjco.v12.i5.323.","journal-title":"World J Clin Oncol"},{"issue":"2","key":"2972_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","volume":"40","author":"JD Wolchok","year":"2022","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022;40(2):127\u201337. https:\/\/doi.org\/10.1200\/JCO.21.02229.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2972_CR17","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1093\/annonc\/mdx190","volume":"28","author":"MF Sanmamed","year":"2017","unstructured":"Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz ME, et al. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Ann Oncol. 2017;28(8):1988\u201395. https:\/\/doi.org\/10.1093\/annonc\/mdx190.","journal-title":"Ann Oncol"},{"key":"2972_CR18","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2147\/JHC.S322289","volume":"8","author":"B Gok Yavuz","year":"2021","unstructured":"Gok Yavuz B, Hasanov E, Lee SS, Mohamed YI, Curran MA, Koay EJ, et al. Current landscape and future directions of biomarkers for immunotherapy in hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:1195\u2013207. https:\/\/doi.org\/10.2147\/JHC.S322289.","journal-title":"J Hepatocell Carcinoma"},{"issue":"3","key":"2972_CR19","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/ijc.25373","volume":"128","author":"M Li","year":"2011","unstructured":"Li M, Li H, Li C, Wang S, Jiang W, Liu Z, et al. Alpha-fetoprotein: a new member of intracellular signal molecules in regulation of the PI3K\/AKT signaling in human hepatoma cell lines. Int J Cancer. 2011;128(3):524\u201332. https:\/\/doi.org\/10.1002\/ijc.25373.","journal-title":"Int J Cancer"},{"issue":"46","key":"2972_CR20","doi-asserted-by":"publisher","first-page":"75749","DOI":"10.18632\/oncotarget.12407","volume":"7","author":"M Zhu","year":"2016","unstructured":"Zhu M, Li W, Guo J, Lu Y, Dong X, Lin B, et al. Alpha fetoprotein antagonises benzyl isothiocyanate Inhibition of the malignant behaviors of hepatocellular carcinoma cells. Oncotarget. 2016;7(46):75749\u201362. https:\/\/doi.org\/10.18632\/oncotarget.12407.","journal-title":"Oncotarget"},{"issue":"1","key":"2972_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-021-01187-y","volume":"14","author":"S Xiong","year":"2021","unstructured":"Xiong S, Dong L, Cheng L. Neutrophils in cancer carcinogenesis and metastasis. J Hematol Oncol. 2021;14(1):173. https:\/\/doi.org\/10.1186\/s13045-021-01187-y.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2972_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","volume":"27","author":"A Tanaka","year":"2017","unstructured":"Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27(1):109\u201318. https:\/\/doi.org\/10.1038\/cr.2016.151.","journal-title":"Cell Res"},{"issue":"1","key":"2972_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-021-00995-8","volume":"14","author":"JY Hong","year":"2022","unstructured":"Hong JY, Cho HJ, Sa JK, Liu X, Ha SY, Lee T, et al. Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. Genome Med. 2022;14(1):1. https:\/\/doi.org\/10.1186\/s13073-021-00995-8.","journal-title":"Genome Med"},{"issue":"1","key":"2972_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00262-008-0516-3","volume":"58","author":"H Cho","year":"2009","unstructured":"Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother. 2009;58(1):15\u201323. https:\/\/doi.org\/10.1007\/s00262-008-0516-3.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"2972_CR25","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, \u0160eruga B, Vera-Badillo FE, Aneja P, Oca\u00f1a A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124. https:\/\/doi.org\/10.1093\/jnci\/dju124.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2972_CR26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3390\/cancers15010257","volume":"15","author":"R Minici","year":"2022","unstructured":"Minici R, Siciliano MA, Ammendola M, Santoro RC, Barbieri V, Ranieri G, et al. Prognostic role of Neutrophil-to-Lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-C reactive protein ratio (LCR) in patients with hepatocellular carcinoma (HCC) undergoing chemoembolizations (TACE) of the liver: the unexplored corner linking tumor microenvironment, biomarkers and interventional radiology. Cancers (Basel). 2022;15(1):257. https:\/\/doi.org\/10.3390\/cancers15010257.","journal-title":"Cancers (Basel)"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02972-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02972-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02972-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T18:11:43Z","timestamp":1750443103000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02972-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2972"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02972-8","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Approval of the research protocol by an Institutional Review Board: This research was in strict accordance with the Declaration of Helsinki and had been sanctioned by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University (2023 - KY \u2212\u20090146). Subsequent to the review process, the Ethics Officer dispensed with the necessity for written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent is not applicable because the data were de-identified in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Registry and the registration no. of the study\/trial"}},{"value":"N\/A.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal studies"}}],"article-number":"1169"}}